



# Expiratory flow limitation in a cohort of highly symptomatic COPD patients

## Document Version

Final published version

[Link to publication record in Manchester Research Explorer](#)

## Citation for published version (APA):

Beech, A., Jackson, N., Dean, J., & Singh, D. (2022). Expiratory flow limitation in a cohort of highly symptomatic COPD patients. *European Respiratory Journal Open Research*, 8(2).

## Published in:

European Respiratory Journal Open Research

## Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

## General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

## Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact [uml.scholarlycommunications@manchester.ac.uk](mailto:uml.scholarlycommunications@manchester.ac.uk) providing relevant details, so we can investigate your claim.





## Early View

Original research article

# Expiratory flow limitation in a cohort of highly symptomatic COPD patients

Augusta Beech, Natalie Jackson, James Dean, Dave Singh

Please cite this article as: Beech A, Jackson N, Dean J, *et al.* Expiratory flow limitation in a cohort of highly symptomatic COPD patients. *ERJ Open Res* 2022; in press (<https://doi.org/10.1183/23120541.00680-2021>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

## **Expiratory flow limitation in a cohort of highly symptomatic COPD patients**

Augusta Beech<sup>1,2</sup>, Natalie Jackson<sup>2</sup>, James Dean<sup>2</sup>, Dave Singh<sup>1,2</sup>

<sup>1</sup> Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

<sup>2</sup> Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK

Corresponding author:

Augusta Beech

Department of Medicine and Health

University of Manchester

Education and Research Centre, M23 9LT, UK

Tel: +44 (0)161 946 4050 Fax +44 (0)1619461459

Email address: [augusta.beech@manchester.ac.uk](mailto:augusta.beech@manchester.ac.uk)

Take home message: EFL, defined by oscillometry, is a common and relatively stable component of disease pathophysiology in highly symptomatic COPD patients. EFL is associated with worse airflow obstruction, small airway resistance, worse quality of life and obesity.

## **Abstract**

### **The question addressed by the study**

Small airway collapse during expiration, known as expiratory flow limitation (EFL), can be detected using oscillometry and is associated with worse clinical outcomes in chronic obstructive pulmonary disease (COPD).

This study investigated the prevalence of EFL in a cohort of highly symptomatic patients, evaluated clinical and lung function characteristics of patients with EFL and studied the repeatability of EFL over 6 months.

### **Materials/patients and methods**

Seventy patients were recruited. Clinical characteristics and lung function metrics were collected at baseline and 6 months. Impulse oscillometry (IOS) was used to detect presence of EFL. Patients were defined as EFL<sup>High</sup> ( $\Delta X5 \geq 0.28$  kPa/L/s); EFL<sup>Intermediate</sup> ( $\Delta X5$  0.1-0.27 kPa/L/s) and EFL<sup>None</sup> ( $\Delta X5 < 0.1$  kPa/L/s).

### **Results**

EFL<sup>High</sup> was present in 47.8% of patients at baseline.  $\Delta X5$  showed excellent repeatability over 6 months ( $\rho = 0.78$ ,  $p < 0.0001$ , ICC = 0.88), with the best repeatability observed in EFL<sup>None</sup> and EFL<sup>High</sup> patients (ICC = 0.77 and 0.65 respectively). Compared to EFL<sup>None</sup> patients, EFL<sup>High</sup> had a higher BMI, worse health-related quality of life and increased peripheral airway resistance. EFL<sup>Intermediate</sup> was more variable over time with less severe physiological impairment.

### **Answer to the question**

Overall, these data indicate that EFL<sup>High</sup> is a common, and relatively stable, component of disease pathophysiology in highly symptomatic COPD patients. EFL<sup>High</sup> was also associated with worse quality of life and obesity.

## Introduction

Chronic obstructive pulmonary disease (COPD) is caused by the inhalation of noxious particles, resulting in airflow obstruction and respiratory symptoms including dyspnoea, cough and sputum production [1]. Small airway disease (SAD) is a key feature of COPD, characterised by immune cell infiltration, mucus hypersecretion and airway remodelling [2, 3]. These pathological changes cause narrowing of the small airways, thereby increasing resistance to airflow [2]. Incomplete emptying of the lung upon expiration due to SAD causes gas trapping, which increases the work of breathing and is associated with increased dyspnoea [4-6]. Small airway closure and collapse during expiration is known as expiratory flow limitation (EFL), which occurs due to regional choke points within the bronchial tree [6]. EFL is associated with increased gas trapping, a greater symptom burden and reduced exercise performance [6-8].

Oscillometry is a non-invasive technique that measures elements of respiratory mechanics during tidal breathing, notably resistance and reactance [5]. A marked change in reactance measured at 5 Hz during expiration compared to inspiration ( $\Delta X_5$ ) is a marker of EFL [9]. A threshold value of  $\geq 0.28 \text{ kPa/L/s}$  ( $\Delta X_5$ ) has been used to define EFL, with patients above this threshold having more gas trapping and a greater symptom burden [6, 9]. A lower  $\Delta X_5$  value of  $> 0.10 \text{ kPa/L/s}$ , which likely detects less severe EFL, is also associated with greater dyspnoea [4]. Previous EFL studies have used broad COPD populations [6, 8, 10, 11], demonstrating associations between EFL and worse clinical characteristics including lower  $\text{FEV}_1$  [6, 11], greater dyspnoea, with increased exercise limitation [4, 6], and increased exacerbation frequency [6, 8].

Dyspnoea is the most common symptom in COPD patients [12]. Airflow obstruction itself causes dyspnoea, but  $\text{FEV}_1$  correlates poorly with dyspnoea [13, 14]. Other contributors to dyspnoea include gas trapping, cardiac dysfunction and muscle wasting [15]. The measurement of EFL, as a cause of gas trapping, may be a useful tool during the investigation of dyspnoea in

COPD patients. Furthermore, EFL can be considered to be a treatable trait [16] in COPD patients with dyspnoea, as it is a component that can be specifically targeted with inhaled treatment.

Previous EFL studies have enrolled broad COPD populations, including individuals with varying degrees of dyspnoea. This study focused on highly symptomatic COPD patients, as the investigation of EFL is most relevant in these individuals. The main aim was to determine the prevalence of EFL in this COPD subgroup. We used different EFL thresholds ( $\geq 0.28$  kPa/L/s and  $> 0.10$  kPa/L/s), and studied the relationships between EFL and other lung function measurements and clinical characteristics. Measurement repeatability over 6 months was evaluated.

## **Methods**

### **Study cohort**

Seventy COPD patients were recruited from the Medicines Evaluation Unit (Manchester University NHS Foundation Trust). Subjects were  $\geq 40$  years old, had a smoking history of  $\geq 10$  pack years, were not using maintenance antibiotics or oral corticosteroids and had no previous asthma diagnosis. Subjects were required to have a modified medical research council (mMRC) score  $\geq 2$  and COPD assessment test (CAT) score  $\geq 15$ . All patients provided written informed consent using protocols approved by local Ethics Committees (16/NW/0836).

### **Study design**

Clinical characteristics were obtained from participants during stable state, defined as no exacerbation or respiratory illness within 4 weeks of the baseline and 6 month visits.

### **Measurements**

CAT [17], mMRC [18] and St George's Respiratory Questionnaire (SGRQ-C) [19] scores assessed symptoms and health related quality of life at both visits. The following procedures were performed at the baseline and 6 month visits; 6 minute walk test (6MWT), fat free mass assessment (BodyStat 1500, BodyStat Ltd, UK), Impulse oscillometry (IOS) (MasterScreen; Erich Jaeger, Hoechbery, DEK), spirometry with reversibility to 400 $\mu$ g of Salbutamol (EasyOne spirometer, NDD medical technologies, CHE), body plethysmography and diffusing capacity of the lungs for carbon monoxide (DLCO) (Vmax, CareFusion, Hoechbery, DEK). Spirometry, body plethysmography, DLCO and 6MWT were performed according to ATS/ERS guidelines [20-23]. Short acting bronchodilators were withheld for 6 hours, long-acting bronchodilators, anticholinergics, theophyllines and leukotriene receptor antagonists were withheld for up to 24 hours prior to lung function testing. IOS was performed as previously described [24], more detail provided in the supplement.  $\Delta X5$  was calculated using the multiple

breath method; mean reactance at 5Hz during inspiration ( $X5_{in}$ ) minus the mean reactance at 5Hz during expiration ( $X5_{ex}$ ). Inspiratory and expiratory data were averaged over multiple tidal breaths, which has been validated against the breath-by-breath method where differences between  $X5_{in}$  and  $X5_{ex}$  are calculated per breath and then averaged; the intraclass correlation coefficient (ICC) = 0.98 [4].

EFL was defined as EFL<sup>High</sup> ( $\Delta X5 \geq 0.28$  kPa/L/s); EFL<sup>Intermediate</sup> ( $\Delta X5$  0.10-0.27 kPa/L/s) and EFL<sup>None</sup> ( $\Delta X5 < 0.10$  kPa/L/s).

### **Statistical analysis**

No formal sample size calculation was performed; this was a pilot study to generate findings that could be confirmed in larger datasets. Non-parametric data were analysed using the Kruskal-Wallis test with Dunn's post hoc analysis and spearman's correlations. Parametric data were analysed using a one-way ANOVA with a Tukey's post hoc test (Prism, GraphPad, 9.0, USA). Variation over time was assessed using Bland-Altman analysis (Prism, GraphPad, 9.0, USA) and ICC of log transformed data (SPSS 25.0, IBM, Armonk, USA). For ICC analysis of  $\Delta X5$ ,  $\log(x+1)$  was used to correct for zero values. ICC values were interpreted as excellent ( $> 0.75$ ), fair to good (0.40–0.75), or poor ( $< 0.40$ ) [25]. A p-value of  $< 0.05$  was considered significant.



## Results

The baseline demography and clinical characteristics are shown in Table 1. The mean age was 64.3 years, 55.7% were male and 42.9% were current smokers. The patients were highly symptomatic with a mean SGRQ score of 53.9, and median CAT and mMRC scores of 21 and 4.0, respectively. The majority of patients (>95%) were using regular maintenance inhaled treatments, with 60% using triple therapy (inhaled corticosteroids plus two long acting bronchodilators). The mean exacerbation rate in the previous 12 months was 1.1. Most patients (94.3%) had at least one concomitant disease, with cardiovascular disease being the most prevalent (supplementary table 1).

### Presence of EFL

69 and 54 patients provided technically acceptable IOS data at baseline and 6 months, respectively. Details of patients who were lost to follow up can be found in the supplement (Supplementary table 2). 33 (47.8%) patients at baseline and 19 (35.2%) at 6 months were classified as EFL<sup>High</sup> (Fig. 1). 17.4% were classed as EFL<sup>Intermediate</sup> and 34.8% as EFL<sup>None</sup> at baseline, while at 6 months these proportions were 20.4% and 44.4% respectively (Fig. 1).

54 patients provided IOS data at both baseline and 6 month visits. There was a positive correlation between  $\Delta X5$  measurements at baseline and 6 months ( $\rho=0.78$ ,  $p<0.0001$ , Fig. 2A), with an ICC of 0.88 indicating excellent repeatability. Other IOS parameters showed positive correlations and excellent repeatability over 6 months (Fig. 2); R5 ( $\rho=0.83$ ,  $p<0.0001$ , ICC=0.90), R20 ( $\rho=0.89$ ,  $p<0.0001$ , ICC=0.93) and R5-20 ( $\rho=0.76$ ,  $p<0.0001$ , ICC=0.85). FEV<sub>1</sub> % predicted and absolute volume also showed excellent correlations between visits ( $\rho=0.84$  and  $0.96$ ,  $p<0.0001$  for both, ICC=0.92 and 0.98 respectively, Fig. 2E&F).

A Bland-Altman analysis between baseline and 6 month measurements of  $\Delta X5$  is presented in Figure 3. Visual inspection of the plot shows that the difference between measurements was

greater for higher EFL measurements. The differences between measurements were not normally distributed, and remained so after log transformation, therefore the mean difference and limits of agreement could not be calculated [26].

Figure 4 shows that 18 (69.2%) out of the 26 EFL<sup>High</sup> patients at baseline remained EFL<sup>High</sup> at 6 months, while 6 (23.1%) moved to EFL<sup>Intermediate</sup>. The majority of EFL<sup>None</sup> patients remained in the same category at 6 months (89.5%). There were significant correlations between baseline and 6 month  $\Delta X5$  measurements for EFL<sup>None</sup>, and EFL<sup>High</sup> patients ( $\rho=0.75$  and  $0.43$ ,  $p<0.001$  and  $0.03$  respectively), with ICC values  $0.77$  and  $0.65$ , respectively. In contrast, there was no correlation for EFL<sup>Intermediate</sup> ( $\rho= -0.03$ ,  $p=0.95$ ,  $ICC=0.07$ ), with only 3 out of 9 patients (33.3%) remaining in the same category at 6 months.

### **EFL and clinical characteristics**

Table 2 shows that EFL<sup>High</sup> patients at baseline had a higher BMI compared to EFL<sup>None</sup> ( $30.2$  vs  $25.8\text{kg/m}^2$ ,  $p<0.01$ ), lower FEV<sub>1</sub> ( $56.8$  vs  $76.3\%$  predicted,  $p<0.0001$ ), lower FEV<sub>1</sub>/FVC ratio ( $47.5$  vs  $57.8\%$ ,  $p<0.001$ ) and higher total SGRQ score ( $57.7$  vs  $48.0$ ,  $p=0.04$ ), with increased scores in the activity and impact domains. Furthermore, a relationship was observed between change in total SGRQ score over 6 months and change in  $\Delta X5$  and R5-R20 ( $\rho=0.42$  and  $0.28$ ,  $p=0.002$  and  $0.04$  respectively, Fig. 5A&B); an increase in  $\Delta X5$  or R5-R20 was associated with an increase in SGRQ score. DLCO and KCO were similar between groups. Presence of concomitant diseases were also mostly similar between groups (supplementary table 1).

### **EFL and other IOS measurements**

Table 2 shows that X5 was more negative and R5, R5-R20 and AX were higher in EFL<sup>High</sup> and EFL<sup>Intermediate</sup> patients compared to EFL<sup>None</sup> at baseline, with measurements being higher in EFL<sup>High</sup> compared to EFL<sup>Intermediate</sup>. Similar results were observed at 6 months (supplementary

table 3).  $\Delta X5$  was positively correlated with R5-R20 at baseline and 6 months ( $\rho=0.84$  and  $0.86$  respectively,  $p<0.0001$  for both, Fig. 5C&D).

### **EFL and lung volumes**

Sixty four patients had technically acceptable data collected for IOS and body plethysmography at baseline. Table 2 shows that both EFL<sup>High</sup> and EFL<sup>Intermediate</sup> patients at baseline displayed higher RV/TLC ratio compared to EFL<sup>None</sup> patients, while EFL<sup>High</sup> patients showed a significantly higher RV % predicted versus EFL<sup>None</sup>. No differences in DLCO or KCO were observed between groups. Similar results were observed at 6 months (see more detail in the online supplement).

Figure 6 shows that  $\Delta X5$  was positively correlated with RV (%) and RV/ TLC at both baseline ( $\rho=0.31$  and  $0.42$ ,  $p=0.01$  and  $<0.001$  respectively) and 6 months ( $\rho=0.29$  and  $0.39$ ,  $p=0.03$  and  $<0.01$  respectively). Negative correlations were observed between  $\Delta X5$  and FEV<sub>1</sub> % predicted (Fig. 6A&D).

## Discussion

In this cohort of highly symptomatic COPD patients, 48% were categorised as EFL<sup>High</sup> at baseline. This finding highlights that EFL is relatively common amongst highly symptomatic COPD patients, and represents a potential target for treatment (a treatable trait [16]). The majority of these EFL<sup>High</sup> patients (69%) remained in the same category or were classified as EFL<sup>Intermediate</sup> (23%) at 6 months, indicating that most EFL<sup>High</sup> patients exhibit some degree of EFL (either “high” or “intermediate”) during longitudinal follow up. Overall, the  $\Delta X5$  ICC of 0.88 indicated excellent repeatability, in line with the stability of EFL phenotype observed in the majority of patients.

The clinical features associated with EFL<sup>High</sup> included reduced quality of life and higher BMI. Additionally, changes in  $\Delta X5$  or R5-R20 were associated with changes in quality of life over 6 months, measures of which have previously been shown as highly repeatable [27]. Previous cross-sectional analyses have shown associations between  $\Delta X5$  and clinical characteristics including dyspnoea and exacerbation rates (n=425 [8] and 147 [6]). Our 6 month longitudinal analysis provides further evidence of the clinical relevance of EFL, showing an association between changes in  $\Delta X5$  and changes in quality of life. Additionally, at baseline EFL<sup>High</sup> patients had higher SGRQ scores driven by worse scores within the activity and impact domains, consistent with the potential for EFL to reduce exercise capacity. Other studies have produced similar findings for the relationship between  $\Delta X5$  and total SGRQ score (n=425 [4]) and the activity domain (n=147 [6]).

Small airways are defined as those <2mm in internal diameter, which are generally found between the 4<sup>th</sup> - 12<sup>th</sup> generation of the bronchial tree [2]. The clinical relevance of EFL was highlighted by worse airflow obstruction and increased small airway resistance (measured by R5-R20) in EFL<sup>High</sup> patients. This finding alone highlights the usefulness of oscillometry measurements in detecting patients with flow limitation at rest which is associated with worse

disease severity [9]. R20 is considered to be a measure of proximal airway resistance [28] and was similar between those with and without EFL (0.36 and 0.39 kPa/L/s respectively,  $p=0.49$ ). Dynamic collapse of the central airways (EDAC) shows similar reactance patterns to EFL reported here, although R20 was numerically lower in COPD patients versus COPD + EDAC (0.33 versus 1.07 cmH<sub>2</sub>O/L/s) [29]. Hence, it is likely that EFL is a continuous process that can occur throughout the airways.

The majority of EFL<sup>None</sup> patients (89%) remained in the same category at 6 months, indicating that the absence of EFL is a relatively stable phenotype. EFL<sup>None</sup> patients had the lowest variability over time for  $\Delta X5$  measurements when assessed using ICC (0.77). ICC is a well-accepted method for assessing repeatability over time. Bland-Altman analysis was designed to compare differences between methods, rather than repeatability of the same method [26]. Nevertheless, visual inspection of the Bland-Altman plot allows the ‘widening trend’ of the differences between measurements with increasing  $\Delta X5$  values to be observed. This trend has been previously been described as ‘proportional difference variability’ [26]. Fluctuations in COPD patients with EFL have been attributed to variation in lung volumes between visits [8]; for the EFL<sup>None</sup> group, the absence of EFL and associated gas trapping or hyperinflation would lead to less variability between visits. Similarly, it has previously been noted, in a sample size of 425 COPD patients, that  $\Delta X5$  measurements show greater variation in individuals with more EFL [4], although formal statistical analysis of reproducibility was not reported. Here, ICC analysis confirms higher variability for  $\Delta X5$  in EFL<sup>High</sup> and EFL<sup>Intermediate</sup> patients (ICC 0.65 and 0.07 respectively) versus EFL<sup>None</sup> patients (ICC 0.77).

The poor reproducibility of EFL<sup>Intermediate</sup> patients (ICC 0.07) was associated with only 33% remaining in the same category. This suggests that EFL<sup>Intermediate</sup> represents a relatively small heterogeneous group (17.4% at baseline) who, on repeated testing, are often classified into the group above or below. Using thresholds can lead to reclassification of individuals over time

due to relatively small changes. Nevertheless, our results (in highly symptomatic COPD patients) suggest that a single  $\Delta X5$  measurement can allocate the majority of patients to either EFL<sup>High</sup> or EFL<sup>None</sup>, with these groups being relatively stable over time. Similarly, in a broad group of COPD patients (not recruited on the basis of symptoms as in our current study), 70% within the EFL<sup>High</sup> group remained in the same category after 2 years [6].

We observed no difference in dyspnoea or CAT scores between EFL groups, in contrast to previous reports [4, 6]. It has been reported that a  $\Delta X5$  threshold of 0.1kPa/L/s predicted breathlessness in COPD patients (sensitivity 64%, specificity 72%), while a threshold of 0.26 kPa/L/s provided a specificity of 95% for detecting breathlessness (area under the curve 0.70) [4]. The absence of any association between EFL and symptoms in the current study can be explained by the inclusion criteria, only allowing patients with higher mMRC and CAT scores to participate, thus reducing the potential to find differences between groups for these patient reported outcome measures. We observed a higher prevalence of EFL<sup>High</sup> (48%) compared to previous studies using the same  $\Delta X5$  threshold (18-37%) [4, 6]. As EFL is known to be associated with a greater symptom burden [6, 8], the recruitment of highly symptomatic patients in this study cohort would be expected to increase the proportion of EFL<sup>High</sup> patients.

There was an association between BMI and  $\Delta X5$ , consistent with a previous report that noted a relationship between obesity and EFL [30]. Obesity is known to influence lung function through mechanical alterations caused by increased adipose deposition around the chest wall and abdomen [4, 30]. This causes decreased chest wall and lung compliance, increased work of breathing and reduced functionality of the diaphragm [31], culminating in a reduction in expiratory reserve volume (ERV) and thereby inducing flow limitation [32]. Other factors may also reduce ERV, thereby promoting lower flow rates and facilitating EFL; For example, chronic heart failure (due to an increase in volume of the heart, vascular engorgement and interstitial oedema) and acute respiratory distress syndrome (due to oedema and atelectasis)

[33]. The presence of comorbidities may therefore represent a source of variation in EFL in some COPD patients. Our results support previous observations in similarly sized cohorts that R5-R20 and  $\Delta X5$  are significantly associated (n=74 [34]), and that EFL<sup>High</sup> (and to a lesser extent EFL<sup>Intermediate</sup>) patients had more gas trapping and pulmonary hyperinflation (in studies with sample sizes n=55 [35], 147 [6] and 74 [34]). The associations between  $\Delta X5$  and small airway resistance, gas trapping and pulmonary hyperinflation [6, 34, 35] support concepts that small airway narrowing (measured by R5-R20) and collapse (measured by EFL) are linked to gas trapping and hyperinflation [36]. There was greater small airway resistance at  $\Delta X5 > 0.10 \text{ kPa/L/s}$ , with increasing severity from EFL<sup>Intermediate</sup> to EFL<sup>High</sup> patients, aligning to the clinical findings showing worse SGRQ scores in EFL<sup>High</sup> patients. Future studies may consider investigating the relationship between EFL and CT scanning parameters of small airway disease and emphysema to further understand our findings.

EFL<sup>High</sup> patients may benefit from inhaled treatments that target the small airways. A recent clinical trial showed that the long acting bronchodilator components of an extra-fine triple therapy formulation (particle size  $< 2 \mu\text{m}$ ) were able to improve R5-R20 with associated improvements in lung volumes [37]. Targeting the small airways may improve dyspnoea and quality of life [38, 39].

Devices utilising the forced oscillation technique (FOT) such as IOS (MasterScreen, DEK) and airwave oscillometry (AOS) (tremoFlow, CA) differ in airflow perturbation signal and have been directly compared in regard to parameter outputs [40]. It has been noted that resistance is typically greater and reactance more abnormal when comparing IOS to AOS, in healthy and patient populations [28, 40]. These differences were more pronounced in post-bronchodilator measurements and in those with more severe airway obstruction [28]. Therefore, it is important to consider methodologies when comparing clinical studies of oscillation mechanics.

This was an exploratory study, with a limited sample size; our findings need to be confirmed in larger datasets. A limitation of this study was patient withdrawal between visits reducing the sample size at 6 months. The thresholds of  $\Delta X5$  used here are based on mean measures of inspiratory and expiratory reactance and although this gives indication EFL presence, it cannot define the precise point(s) during the expiratory limb of tidal breathing at which EFL occurs. This, as described by Lorx et al, highlights further heterogeneity within flow-limited patients [41]. Furthermore, using the multiple breath method to define EFL and trichotomizing patients into categories may classify some patients as EFL<sup>Intermediate</sup> or EFL<sup>High</sup> despite not meeting the  $\Delta X5$  threshold for every breath.

## **Conclusion**

In conclusion, we report that EFL<sup>High</sup> was present in approximately half of the individuals in this highly symptomatic COPD cohort. EFL<sup>High</sup> and EFL<sup>None</sup> were relatively stable phenotypes over time. EFL<sup>High</sup> was associated with worse small airway disease, a reduced quality of life and higher BMI. Overall, these data indicate that EFL<sup>High</sup> is a common, and relatively stable, component of disease pathophysiology in highly symptomatic COPD patients.



## **Statements**

### **Acknowledgements**

Dave Singh and Augusta Beech are supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC).

### **Statement of Ethics**

The study was conducted according to the guidelines of the Declaration of Helsinki, and the study protocol was reviewed and approved by the Ethics Committee of HRA, North West – Preston Research Ethics Committee (protocol code: 16/NW0836, date of approval: 13.12.2016). Written informed consent was obtained from all subjects involved in the study.

### **Conflict of Interest Statement**

DS has received sponsorship to attend and speak at international meetings, honoraria for lecturing or attending advisory boards from the following companies: Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Epiendo, Genentech, GlaxoSmithKline, Glenmark, Gossamerbio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Teva, Theravance and Verona. AB, NJ and JD have no conflicts of interest to declare.

### **Funding Sources**

This work was supported by AstraZeneca (AZ).

### **Author Contributions**

AB and DS were responsible for the concept and design of study. AB, NJ and DS were involved in data acquisition. AB analysed the data and DS oversaw all analyses. AB and DS were responsible for data interpretation and drafting the manuscript. JD revised the manuscript critically for intellectual content. All authors have approved the final version to be published and are jointly accountable for all aspects of the work.

**Data availability statement**

The datasets generated and/or analysed during the current study and additional related documents are not publicly available.

## Tables

**Table 1.** Baseline clinical characteristics, n=70<sup>a</sup>

| Clinical<br>Characteristic  | n=70                | Lung function parameter                 | n=70                   |
|-----------------------------|---------------------|---|------------------------|
| Age                         | 64.3 (61.9-66.6)    | Post-BD FEV <sub>1</sub> (% predicted)  | 65.6 (16.9)            |
| Gender (% M)                | 55.7                | Post-BD FEV <sub>1</sub> (L)            | 1.7 (0.6)              |
| BMI (kg/m <sup>2</sup> )    | 27.96 (26.54-29.38) | Post-BD FVC (% predicted)               | 100.2 (96.3-104.0)     |
| FFMI                        | 17.99 (16.95-19.04) | Post-BD FVC (L)                         | 3.3 (3.1-3.5)          |
| Smoking Status (% Current)  | 42.9                | FEV <sub>1</sub> reversibility (%)      | 10.9 (8.2-13.6)        |
| Pack Years                  | 43.9 (39.3-48.6)    | FEV <sub>1</sub> reversibility (mls)    | 143.3 (109.7-176.9)    |
| Exacerbation (Previous 12m) | 1.1 (0.8-1.4)       | Post-BD FEV <sub>1</sub> /FVC ratio (%) | 52.6 (49.9-55.3)       |
| 0 (%)                       | 38.6                | R5 (kPa/L/s)                            | 0.60 (0.56-0.65)       |
| 1 (%)                       | 35.7                | R20 (kPa/L/s)                           | 0.37 [0.23-0.66]       |
| ≥2 (%)                      | 25.7                | R5-R20 (kPa/L/s)                        | 0.22 (0.19-0.25)       |
| ICS Use (% patients)        | 74.3                | AX                                      | 2.96 (2.50-3.42)       |
| LABA+LAMA+ICS (%)           | 60.0                | X5 (kPa/L/s)                            | -0.30 [-0.92-(-0.07)]  |
| LABA+LAMA (%)               | 8.6                 | ΔX5 (kPa/L/s)                           | 0.25 [-0.05-1.48]      |
| ICS + LABA (%)              | 11.4                | TLC (L)                                 | 6.04 [3.75-9.47]       |
| ICS + LAMA (%)              | 1.4                 | TLC (% predicted)                       | 101.80 [73.89-144.50]  |
| ICS only (%)                | 1.4                 | FRC(L)                                  | 3.59 [1.69-6.79]       |
| LABA only (%)               | 0.0                 | FRC (% predicted)                       | 117.10 (109.70-124.60) |
| LAMA only (%)               | 12.9                | RV (L)                                  | 2.72 [1.48-5.58]       |
| No inhaled medication (%)   | 4.3                 | RV (% predicted)                        | 122.80 [74.00-234.60]  |
| mMRC                        | 4.0 [2.0-4.0]       | RV:TLC                                  | 48.61 (46.37-50.86)    |
| CAT                         | 21.0 [15.0-39.0]    | DLCO (mmol/min/kPa)                     | 4.25 [1.60-13.10]      |
| SGRQ total                  | 53.86 (50.15-57.57) | DLCO (% predicted)                      | 49.00 [21.00-108.00]   |
| SGRQ symptoms               | 67.31 (63.46-71.16) | KCO (mmol/min/kPa/L)                    | 0.96 [0.33-4.26]       |
| SGRQ activity               | 72.00 (67.71-76.29) | KCO (% predicted)                       | 64.69 [26.00-148.00]   |
| SGRQ impact                 | 39.60 (35.23-43.97) | VA (L)                                  | 4.55 (4.29-4.80)       |
| Chronic bronchitis (%)      | 77.1                | VA (%)                                  | 76.77 (73.92-79.63)    |
| 6MWT Distance (m)           | 343.5 [122.0-534.0] |   |                        |

|                         |                      |
|-------------------------|----------------------|
| <b>Fibrinogen (g/L)</b> | 3.30 [0.00-6.55]     |
| <b>IgE (kIU/L)</b>      | 60.00 [0.00-1297.00] |
| <b>NLR</b>              | 2.02 [0.92-6.79]     |

---

Data presented as mean (95% CI), median [range] or percentage as appropriate.

<sup>a</sup>5 patients could not produce technically acceptable results for lung volumes and 1 for IOS, 4 patients do not have data for FFMI and 4 could not complete the 6MWT.

Abbreviations: AX, reactance area; BD, bronchodilator; BMI, body mass index; CAT, COPD assessment test; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FFMI, fat free mass index; FRC, functional residual capacity; FVC, forced vital capacity; ICS, inhaled corticosteroids; IgE, immunoglobulin E; KCO, carbon monoxide transfer coefficient; LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist; mMRC, modified medical research council questionnaire; NLR, neutrophil-lymphocyte ratio; RV, residual volume; R5, resistance at 5Hz; R20, resistance at 20Hz; SGRQ, St George's respiratory questionnaire; TLC, total lung capacity; VA, alveolar volume; X5, reactance at 5Hz,  $\Delta X5$ , difference in total reactance between inspiration and expiration; 6MWT, 6 minute walk test.

**Table 2.** Baseline characteristics in different EFL groups, n=69<sup>a</sup>

| Characteristic                          | EFL <sup>None</sup> (n=24) | EFL <sup>Intermediate</sup> (n=12) | EFL <sup>High</sup> (n=33)                 | ANOVA   |
|---|----------------------------|------------------------------------|--|---------|
|   |                            |                                    |  | p-value |
| Age                                     | 64.9 (61.6-68.2)           | 63.6 (58.8-68.3)                   | 65.9 (63.3-68.5)                           | 0.64    |
| Gender (% M)                            | 58.3                       | 66.7                               | 51.5                                       | 0.79    |
| BMI (kg/m <sup>2</sup> )                | 25.8 (23.9-27.8)           | 27.93 (24.3-31.5)                  | <sup>bb</sup> 30.2 (28.2-32.2)             | 0.01    |
| FFMI                                    | 17.44 [12.20-24.89]        | 17.50 [5.52-22.90]                 | 18.05 [13.22-31.65]                        | 0.56    |
| Smoking Status (% Current)              | 50.0                       | 58.3                               | 30.3                                       | 0.15    |
| Pack Years                              | 36.9 (30.6-43.2)           | 42.3 (42.6-62.0)                   | 45.7 (37.8-53.6)                           | 0.06    |
| Exacerbation (Previous 12m)             | 1.0 [0.0-4.0]              | 1.0 [0.0-3.0]                      | 0.0 [0.0-4.0]                              | 0.06    |
| ICS Use (% patients)                    | 75.0                       | 58.3                               | 81.8                                       | 0.27    |
| mMRC                                    | 4.0 [2.0-4.0]              | 4.0 [2.0-4.0]                      | 4.0 [2.0-4.0]                              | 0.22    |
| CAT                                     | 20.0 [15.0-31.0]           | 22.50 [15.0-30.0]                  | 21.0 [15.0-32.0]                           | 0.47    |
| SGRQ total                              | 48.0 (42.1-53.9)           | 55.8 (46.0-65.7)                   | <sup>b</sup> 57.7 (52.5-62.9)              | 0.05    |
| SGRQ symptoms                           | 66.9 (60.1-73.6)           | 69.7 (15.6-81.8)                   | 66.1 (60.7-71.6)                           | 0.80    |
| SGRQ activity                           | 65.8 (59.5-72.1)           | 68.6 (56.1-81.1)                   | <sup>b</sup> 77.1 (70.6-83.6)              | 0.05    |
| SGRQ impact                             | 31.1 (24.0-38.2)           | 43.3 (33.0-53.6)                   | <sup>b</sup> 43.4 (37.1-49.8)              | 0.02    |
| Chronic bronchitis (%)                  | 83.3                       | 66.7                               | 75.8                                       | 0.53    |
| 6MWT Distance (m)                       | 368.5 [160.0-516.0]        | 336.5 [240.0-534.0]                | 338.0 [112.0-436.0]                        | 0.58    |
| Post-BD FEV <sub>1</sub> (% predicted)  | 76.3 (71.5-81.1)           | 66.6 (56.5-76.6)                   | <sup>b</sup> <sup>b</sup> 56.8 (51.1-62.5) | <0.01   |
| Post-BD FEV <sub>1</sub> (L)            | 2.1 (1.8-2.3)              | 1.7 (1.5-2.0)                      | <sup>b</sup> <sup>b</sup> 1.5 (1.3-1.6)    | <0.01   |
| Post-BD FVC (% predicted)               | 106.2 (100.5-112.0)        | 96.8 (85.2-108.3)                  | 96.6 (90.9-102.3)                          | 0.06    |
| Post-BD FVC (L)                         | 3.6 (3.2-4.0)              | 3.2 (2.7-3.6)                      | 3.1 (2.8-3.4)                              | 0.08    |
| FEV <sub>1</sub> reversibility (%)      | 8.9 (5.1-12.4)             | 10.7 (4.0-17.4)                    | 12.6 (8.0-17.3)                            | 0.72    |
| FEV <sub>1</sub> reversibility (mls)    | 146.2 (81.82-210.5)        | 155.0 (33.1-276.9)                 | 136.1 (95.1-177.0)                         | 0.92    |
| Post-BD FEV <sub>1</sub> /FVC ratio (%) | 57.8 (54.4-61.3)           | 55.8 (49.7-62.0)                   | <sup>b</sup> <sup>b</sup> 47.5 (43.3-51.7) | <0.01   |

|                             |                       |  |  |       |
|-----------------------------|-----------------------|--|--|-------|
| <b>Fibrinogen (g/L)</b>     | 3.21 [2.20-4.60]      | 3.29 [0.00-4.30]                           | 3.42 [0.00-4.60]   | 0.41  |
| <b>IgE (kIU/L)</b>          | 48.50 [0.00-1297.00]  | 65.00 [7.00-837.00]                        | 66.00 [3.00-858.00]  | 0.64  |
| <b>NLR</b>                  | 2.00 [0.92-4.98]      | 1.84 [1.13-3.04]                           | 2.26 [0.99-6.79]   | 0.46  |
| <b>R5 (kPa/L/s)</b>         | 0.45 [0.21-0.74]      | <sup>c</sup> 0.65 [0.48-1.02]              | <sup>b</sup> <sup>b</sup> 0.69 [0.44-1.02]                             | <0.01 |
| <b>R20 (kPa/L/s)</b>        | 0.36 (0.33-0.39)      | 0.40 (0.32-0.48)                           | 0.39 (0.36-0.42)   | 0.41  |
| <b>R5-R20 (kPa/L/s)</b>     | 0.08 (0.06-0.11)      | <sup>c</sup> <sup>c</sup> 0.21 (0.15-0.27) | <sup>b</sup> <sup>b</sup> , <sup>d</sup> <sup>d</sup> 0.33 (0.29-0.36) | <0.01 |
| <b>AX</b>                   | 0.95 [0.13-3.71]      | <sup>c</sup> 2.38 [0.94-6.38]              | <sup>b</sup> <sup>b</sup> , <sup>d</sup> 8.43 [1.91-8.52]              | <0.01 |
| <b>X5 (kPa/L/s)</b>         | -0.15 [-0.34 (-0.07)] | <sup>c</sup> -0.28 [-0.46-(-0.21)]         | <sup>b</sup> <sup>b</sup> -0.41 [-0.92-(-0.23)]                        | <0.01 |
| <b>ΔX5 (kPa/L/s)</b>        | 0.03 [-0.05-0.08]     | <sup>c</sup> 0.20 [0.15-0.27]              | <sup>b</sup> <sup>b</sup> , <sup>d</sup> <sup>d</sup> 0.54 [0.29-1.48] | <0.01 |
| <b>TLC (L)</b>              | 5.90 [4.29-9.14]      | 6.09 [4.53-9.47]                           | 6.00 [3.75-8.60]   | 0.90  |
| <b>TLC (% predicted)</b>    | 101.50 [74.92-130.50] | 99.60 [77.83-131.30]                       | 102.80 [73.89-144.50]  | 0.80  |
| <b>FRC (L)</b>              | 3.44 (3.10-3.79)      | 3.86 (3.14-4.59)                           | 3.89 (3.46-4.31)   | 0.27  |
| <b>FRC (% predicted)</b>    | 105.50 (96.54-114.50) | 122.50 (104.00-141.10)                     | 124.50 (111.50-137.5)  | 0.06  |
| <b>RV (L)</b>               | 2.55 [1.85-4.28]      | 3.15 [1.93-5.58]                           | 3.26 [1.48-5.14]   | 0.06  |
| <b>RV (% predicted)</b>     | 114.80 (103.1-126.5)  | 132.60 (112.60-152.60)                     | <sup>b</sup> 143.60 (127.60-159.60)                                    | 0.02  |
| <b>RV:TLC</b>               | 0.44 (0.41-0.47)      | <sup>c</sup> 0.51 (0.46-0.55)              | <sup>b</sup> <sup>b</sup> 0.52 (0.49-0.55)                             | <0.01 |
| <b>DLCO (mmol/min/kPa)</b>  | 4.15 [1.80-9.30]      | 4.50 [2.70-11.50]                          | 4.20 [1.60-13.10]  | 0.47  |
| <b>DLCO (% predicted)</b>   | 53.04 (44.21-61.87)   | 58.74 (45.50-71.98)                        | 51.60 (45.15-58.04)  | 0.56  |
| <b>KCO (mmol/min/kPa/L)</b> | 0.88 [0.33-1.76]      | 1.12 [0.71-2.14]                           | 0.91 [0.45-4.26]   | 0.11  |
| <b>KCO (% predicted)</b>    | 62.88 [26.00-124.50]  | 73.00 [53.00-148.00]                       | 64.34 [33.11-115.00]   | 0.33  |
| <b>VA (L)</b>               | 4.91 (4.41-5.41)      | 4.40 (3.92-4.88)                           | 4.26 (3.93-4.58)   | 0.05  |
| <b>VA (% predicted)</b>     | 81.02 (76.57-85.48)   | 75.65 (69.44-81.86)                        | 73.52 (69.03-78.00)  | 0.06  |

---

Data presented as mean (95% CI), median [range] or percentage as appropriate. p-value corresponds to one way ANOVA, Kruskal-wallis or chi-squared test as appropriate. EFL defined as EFL<sup>High</sup> ( $\Delta X5 \geq 0.28$  kPa/L/s), EFL<sup>Intermediate</sup> ( $\Delta X5$  0.10-0.27 kPa/L/s) and EFL<sup>None</sup> ( $\Delta X5 < 0.10$  kPa/L/s).

<sup>a</sup> 5 patients did not produce technically acceptable results for lung volumes, 4 had no data for FFMI and 4 could not complete the 6MWT.

<sup>b</sup> =  $p < 0.05$ , <sup>b</sup> <sup>b</sup> =  $p < 0.01$  (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>High</sup>

<sup>c</sup> =  $p < 0.05$ , <sup>c</sup> <sup>c</sup> =  $p < 0.01$  (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>Intermediate</sup>

<sup>d</sup> =  $p < 0.05$ , <sup>d</sup> <sup>d</sup> =  $p < 0.01$  (using Tukey's or Dunns post-hoc test) for EFL<sup>Intermediate</sup> vs EFL<sup>High</sup>

Abbreviations: AX, reactance area; BD, bronchodilator; BMI, body mass index; CAT, COPD assessment test; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FFMI, fat free mass index; FRC, functional residual capacity; FVC, forced vital capacity; ICS, inhaled corticosteroids; IgE, immunoglobulin E; KCO, carbon monoxide transfer coefficient; LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist; mMRC, modified medical research council questionnaire; NLR, neutrophil-lymphocyte ratio; RV, residual volume; R5, resistance at 5Hz; R20, resistance at 20Hz; SGRQ, St George's respiratory questionnaire; TLC, total lung capacity; VA, alveolar volume; X5, reactance at 5Hz,  $\Delta X5$ , difference in total reactance between inspiration and expiration; 6MWT, 6 minute walk test.

## References

1. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, Lopez Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J* 2019; 53(5).
2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350(26): 2645-2653.
3. Higham A, Quinn AM, Cancado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. *Respir Res* 2019; 20(1): 49.
4. Aarli BB, Calverley PM, Jensen RL, Eagan TM, Bakke PS, Hardie JA. Variability of within-breath reactance in COPD patients and its association with dyspnoea. *Eur Respir J* 2015; 45(3): 625-634.
5. Jetmalani K, Timmins S, Brown NJ, Diba C, Berend N, Salome CM, Wen FQ, Chen P, King GG, Farah CS. Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 939-945.
6. Dean J, Kolsum U, Hitchen P, Gupta V, Singh D. Clinical characteristics of COPD patients with tidal expiratory flow limitation. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1503-1506.
7. Thomas M, Decramer, M., O'Donnell, DE. . No room to breathe: the importance of lung hyperinflation in COPD. *Primary Care Respiratory Journal* 2013; 22(1): 101-111.



8. Aarli BB, Calverley PM, Jensen RL, Dellaca R, Eagan TM, Bakke PS, Hardie JA. The association of tidal EFL with exercise performance, exacerbations, and death in COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2179-2188.
9. Dellaca RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. *Eur Respir J* 2004; 23(2): 232-240.
10. Paredi P, Goldman M, Alamen A, Ausin P, Usmani OS, Pride NB, Barnes PJ. Comparison of inspiratory and expiratory resistance and reactance in patients with asthma and chronic obstructive pulmonary disease. *Thorax* 2010; 65(3): 263-267.
11. Kanda S, Fujimoto K, Komatsu Y, Yasuo M, Hanaoka M, Kubo K. Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. *Intern Med* 2010; 49(1): 23-30.
12. Punekar YS MH, Small M, Holbrook T, Wood R, Naya I, Valle M. Prevalence and Burden of Dyspnoea Among Patients with Chronic Obstructive Pulmonary Disease in Five European Countries. *Pulmonary Therapy* 2016; 2: 59-72.
13. Agustí A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J, Evaluation of CLtIPSEi. Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res* 2010; 11: 122.
14. Saadeh C, Saadeh C, Cross B, Gaylor M, Griffith M. Advantage of impulse oscillometry over spirometry to diagnose chronic obstructive pulmonary disease and monitor pulmonary responses to bronchodilators: An observational study. *SAGE Open Med* 2015; 3: 2050312115578957.
15. Jolley CJ, Moxham J. A physiological model of patient-reported breathlessness during daily activities in COPD. *Eur Respir Rev* 2009; 18(112): 66-79.

16. Agustí A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, Humbert M, Jones P, Gibson PG, Vestbo J, Beasley R, Pavord ID. Treatable traits: toward precision medicine of chronic airway diseases. *Eur Respir J* 2016; 47(2): 410-419.
17. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. *The European respiratory journal* 2009; 34(3): 648-654.
18. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 158(4): 1185-1189.
19. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992; 145(6): 1321-1327.
20. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* 2019; 200(8): e70-e88.
21. Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, MacIntyre NR, Thompson BR, Wanger J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017; 49(1).
22. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes. *Eur Respir J* 2005; 26(3): 511-522.

23. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *American journal of respiratory and critical care medicine* 2002; 116: 111-117.
24. Borrill ZL, Houghton CM, Woodcock AA, Vestbo J, Singh D. Measuring bronchodilation in COPD clinical trials. *Br J Clin Pharmacol* 2005; 59(4): 379-384.
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986; 1(8476): 307-310.
26. Giavarina D. Understanding Bland Altman analysis. *Biochem Med (Zagreb)* 2015; 25(2): 141-151.
27. Anderson WH, Ha JW, Couper DJ, O'Neal WK, Barr RG, Bleecker ER, Carretta EE, Cooper CB, Doerschuk CM, Drummond MB, Han MK, Hansel NN, Kim V, Kleeerup EC, Martinez FJ, Rennard SI, Tashkin D, Woodruff PG, Paine R, 3rd, Curtis JL, Kanner RE, Group SR. Variability in objective and subjective measures affects baseline values in studies of patients with COPD. *PLoS One* 2017; 12(9): e0184606.
28. Kuo CR, Jabbal S, Lipworth B. I Say IOS You Say AOS: Comparative Bias in Respiratory Impedance Measurements. *Lung* 2019; 197(4): 473-481.
29. Fielding DI, Travers J, Nguyen P, Brown MG, Hartel G, Morrison S. Expiratory reactance abnormalities in patients with expiratory dynamic airway collapse: a new application of impulse oscillometry. *ERJ Open Res* 2018; 4(4).
30. Franssen FM, O'Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. *Thorax* 2008; 63(12): 1110-1117.
31. Babb TG, Wyrick BL, DeLorey DS, Chase PJ, Feng MY. Fat distribution and end-expiratory lung volume in lean and obese men and women. *Chest* 2008; 134(4): 704-711.
32. Ferretti A, Giampiccolo P, Cavalli A, Milic-Emili J, Tantucci C. Expiratory flow limitation and orthopnea in massively obese subjects. *Chest* 2001; 119(5): 1401-1408.

33. Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. *Eur Respir J* 2005; 25(1): 186-199.
34. Mikamo M, Shirai T, Mori K, Shishido Y, Akita T, Morita S, Asada K, Fujii M, Suda T. Predictors of expiratory flow limitation measured by forced oscillation technique in COPD. *BMC Pulm Med* 2014; 14: 23.
35. D'Ascanio M, Viccaro F, Calabro N, Guerrieri G, Salvucci C, Pizzirusso D, Mancini R, De Vitis C, Pezzuto A, Ricci A. Assessing Static Lung Hyperinflation by Whole-Body Plethysmography, Helium Dilution, and Impulse Oscillometry System (IOS) in Patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 2583-2589.
36. Smith BM, Hoffman EA, Basner RC, Kawut SM, Kalhan R, Barr RG. Not all measures of hyperinflation are created equal: lung structure and clinical correlates of gas trapping and hyperexpansion in COPD: the Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study. *Chest* 2014; 145(6): 1305-1315.
37. Dean J, Panainte C, Khan N, Singh D. The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD. *Respir Res* 2020; 21(1): 323.
38. Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, Olivieri D. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. *Int J Chron Obstruct Pulmon Dis* 2011; 6: 503-509.
39. Singh D. Small Airway Disease in Patients with Chronic Obstructive Pulmonary Disease. *Tuberc Respir Dis (Seoul)* 2017; 80(4): 317-324.
40. Lundblad LKA, Miletic R, Piitulainen E, Wollmer P. Oscillometry in Chronic Obstructive Lung Disease: In vitro and in vivo evaluation of the impulse oscillometry and tremoflo devices. *Sci Rep* 2019; 9(1): 11618.

41. Lox A, Czovek D, Gingl Z, Makan G, Radics B, Bartusek D, Szigeti S, Gal J, Losonczy G, Sly PD, Hantos Z. Airway dynamics in COPD patients by within-breath impedance tracking: effects of continuous positive airway pressure. *Eur Respir J* 2017; 49(2).




Figure 1: Proportion of patients in different EFL groups at baseline and 6 months. EFL groups defined as;  $\Delta X5 < 0.10$  kPa/L/s (EFLNone),  $\Delta X5 0.10-0.27$  kPa/L/s (EFLIntermediate) and  $\Delta X5 \geq 0.28$  kPa/L/s (EFLHigh), n=69 and 54 respectively. EFL, expiratory flow limitation.




Figure 2: Association between lung function parameters over 6 months;  $\Delta X5$  (A), R5 (B), R20 (C), R5-R20 (D), FEV1 (% predicted) (D) and FEV1 (absolute) (E). n=64\*. p-value corresponds to a spearman's rank test and Pearson's correlation for nonparametric and parametric data, respectively. p<0.05 was considered statistically significant. FEV1, forced expiratory volume in 1 second; R5, resistance at 5Hz; R20, resistance at 20Hz;  $\Delta X5$ , difference in total reactance between inspiration and expiration at 5Hz\*10 patients did not provide IOS data at 6 months




Figure 3: Bland-Altman plot of the difference versus the mean of two repeat measurements of  $\Delta X5$  over 6 months.  $n=54$ .  $\Delta X5$ , difference in total reactance between inspiration and expiration at 5Hz






Figure 4: Repeatability of  $\Delta X5$  within different groups; EFLNone (A), EFLIntermediate (B) and EFLHigh (C). EFL groups defined as;  $\Delta X5 < 0.10$  kPa/L/s (EFLNone),  $\Delta X5$  0.10-0.27 kPa/L/s (EFLIntermediate) and  $\Delta X5 \geq 0.28$  kPa/L/s (EFLHigh), n=54. ICC, intraclass correlation;  $\Delta X5$ , difference in total reactance between inspiration and expiration at 5Hz




Figure 5: Change in  $\Delta X5$  (A) and R5-R20 (B) over 6 months associated with a change in total SGRQ scores,  $n=54$  for both. Association between  $\Delta X5$  and R5-R20 at baseline (C) and 6 months (D),  $n=69$  and  $54$ , respectively.  $p$ -value corresponds to a spearman's rank test.  $p<0.05$  was considered statistically significant. R5, resistance at 5Hz; R20, resistance at 20Hz; SGRQ, St. George's respiratory questionnaire;  $\Delta X5$ , difference in total reactance between inspiration and expiration at 5Hz




Figure 6: Association between  $\Delta X5$  and other lung function parameters at baseline; FEV1 (% predicted) (A), RV (% predicted) (B), RV:TLC ratio (C), and 6 months; FEV1 (% predicted) (D), RV (% predicted) (E), RV:TLC ratio (F).  $n=64$  and  $54^*$  respectively.  $p$ -value corresponds to a spearman's rank test.  $p < 0.05$  was considered statistically significant. FEV1, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity;  $\Delta X5$ , difference in total reactance between inspiration and expiration at 5Hz.\*1 patient did not have RV data at 6 months

## Online Data Supplement

### Expiratory flow limitation in a cohort of highly symptomatic COPD patients

Augusta Beech<sup>1,2</sup>, Natalie Jackson<sup>2</sup>, James Dean<sup>2</sup>, Dave Singh<sup>1,2</sup>

<sup>1</sup>Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK

<sup>2</sup>Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK

Corresponding author:

Augusta Beech

Department of Medicine and Health

University of Manchester

Education and Research Centre, M23 9LT, UK

Tel: +44 (0)161 946 4050 Fax +44 (0)1619461459

Email address: [augusta.beech@manchester.ac.uk](mailto:augusta.beech@manchester.ac.uk)

Number of supplementary tables: 3

Number of supplementary figures: 0

Word count: 227

## **Methods**

### **Impulse Oscillometry (IOS)**

Patients were required to support their cheeks and use a free-flow mouthpiece to depress the tongue while impulses were applied during tidal breathing for 30 seconds in a seated position - this process was repeated to achieve three technically acceptable and reproducible attempts of which the means were reported. IOS was performed prior to all other lung function measurements.

## **Results**

### **EFL and other IOS measurements at 6 months**

At 6 months R5 and AX were elevated in EFL<sup>High</sup> patients compared to both EFL<sup>None</sup> and EFL<sup>Intermediate</sup> (0.72 vs 0.44 and 0.56 kPa/L/s,  $p=0.02$  and  $<0.0001$  and  $0.02$ . 4.48 vs 1.03 and 2.12 kPa/L/s,  $p<0.001$  and  $0.04$  respectively, supplementary table 3). R5-R20 was elevated in EFL<sup>High</sup> patients compared to EFL<sup>None</sup> and EFL<sup>Intermediate</sup> (0.35 vs 0.09 and 0.19 kPa/L/s,  $p<0.0001$  for both, supplementary table 3). R5-R20 was also higher in EFL<sup>Intermediate</sup> when compared to EFL<sup>None</sup> (0.19 vs 0.09 kPa/L/s,  $p=0.01$ , supplementary table 3). Furthermore, X5 was more negative in EFL<sup>High</sup> patients compared to both EFL<sup>None</sup> patients (-0.39 vs -0.17 kPa/L/s,  $p<0.0001$ , supplementary table 3).

### **EFL and lung volumes at 6 months**

At 6 months, 53 patients had technically acceptable data collected for both IOS and body plethysmography. RV/TLC ratio was significantly elevated in EFL<sup>High</sup> compared to EFL<sup>None</sup> patients (0.55 vs 0.45 respectively,  $p<0.01$ , supplementary table 3). No differences in DLCO or KCO were observed between groups.

## Tables

**Supplementary table 1.** Baseline comorbidities, n=70

| <b>Characteristic</b>                                 | <b>All<br/>(n=70)<br/>n (%)</b> | <b>EFL<sup>None</sup><br/>(n=24)<br/>n (%)</b> | <b>EFL<sup>Intermediate</sup><br/>(n=12)<br/>n (%)</b> | <b>EFL<sup>High</sup><br/>(n=33)<br/>n (%)</b> | <b>P-<br/>value</b> |
|---|---------------------------------|--|--|--|---------------------|
| <b>Patients with at least one concomitant disease</b> | 66<br>(94.3)                    | 24 (100.0)                                     | 11 (91.7)  | 31 (93.9)                                      | 0.41                |
| <b>Ischaemic heart disease</b>                        | 18<br>(25.7)                    | 8 (33.3)                                       | 3 (25.0)   | 7 (21.2)                                       | 0.59                |
| <b>Myocardial ischaemia</b>                           | 13<br>(18.6)                    | 4 (16.7)                                       | 2 (16.7)   | 7 (21.2)                                       | 0.89                |
| <b>Angina pectoris</b>                                | 7 (10.0)                        | 4 (16.7)                                       | 0  | 3 (9.1)  | 0.28                |
| <b>Myocardial infarction</b>                          | 10<br>(14.3)                    | 5 (20.8)                                       | 2 (16.7)   | 3 (9.1)  | 0.45                |
| <b>Cardiac failure</b>                                | 0                               | 0  | 0  | 0  | N/A                 |
| <b>Cardiovascular disease</b>                         | 52<br>(74.3)                    | 16 (66.7)                                      | 10 (83.3)  | 25 (75.8)                                      | 0.53                |
| <b>Hypertension</b>                                   | 32<br>(45.7)                    | 6 (25.0)                                       | <sup>b</sup> 8 (66.7)                                  | <sup>a</sup> 17 (51.5)                         | 0.04                |
| <b>Hypercholesterolemia</b>                           | 38<br>(52.3)                    | 13 (54.2)                                      | 6 (50.0)   | 18 (54.5)                                      | 0.96                |
| <b>Coronary artery disease</b>                        | 0                               | 0  | 0  | 0  | N/A                 |
| <b>Pulmonary hypertension</b>                         | 0                               | 0  | 0  | 0  | N/A                 |
| <b>Peripheral vascular disease</b>                    | 5 (7.1)                         | 4 (16.7)                                       | 1 (8.3)  | 0  | 0.06                |
| <b>Cerebrovascular disease</b>                        | 0                               | 0  | 0  | 0  | N/A                 |
| <b>Stroke (including transient ischaemic attack)</b>  | 9 (12.9)                        | 2 (8.3)  | 3 (25.0)   | 4 (12.1)                                       | 0.37                |
| <b>Irregular heartbeat</b>                            | 3 (4.3)                         | 1 (4.2)  | 0  | 2 (6.1)  | 0.68                |
| <b>Diabetes</b>                                       | 8 (11.4)                        | 1 (4.2)  | 3 (25.0)   | 4 (12.1)                                       | 0.09                |
| <b>Obesity</b>  | 23<br>(32.9)                    | 4 (16.7)                                       | 5 (41.7)   | 14 (42.4)                                      | 0.10                |
| <b>Obstructive sleep apnoea</b>                       | 1 (1.4)                         | 0  | 0  | 1 (3.0)  | 0.57                |
| <b>Anaemia</b>  | 4 (5.7)                         | 3 (12.5)                                       | 0  | 1 (3.0)  | 0.20                |

|   |              |          |          |           |      |
|---|--------------|----------|----------|-----------|------|
| <b>Osteoarthritis, osteopenia or osteoporosis</b> | 27<br>(38.6) | 9 (37.5) | 3 (25.0) | 14 (42.4) | 0.57 |
| <b>Gastro-oesophageal reflux disease</b>          | 17<br>(24.3) | 6 (25.0) | 2 (16.7) | 9 (27.3)  | 0.77 |
| <b>Psychological disturbances</b>                 | 23<br>(32.9) | 8 (33.3) | 5 (41.7) | 10 (30.3) | 0.79 |
| <b>Depression</b>                                 | 19<br>(27.1) | 7 (29.2) | 4 (33.3) | 8 (24.2)  | 0.81 |
| <b>Anxiety</b>                                    | 9 (12.9)     | 3 (12.5) | 2 (16.7) | 4 (12.1)  | 0.92 |
| <b>Insomnia</b>                                   | 1 (1.4)      | 0        | 1 (8.3)  | 0         | 0.09 |

Data presented as n (%). p-value corresponds to a chi-squared test. EFL defined as EFL<sup>High</sup> ( $\Delta X5 \geq 0.28$  kPa/L/s), EFL<sup>Intermediate</sup> ( $\Delta X5$  0.10-0.27 kPa/L/s) and  $\geq$  EFL<sup>None</sup> ( $\Delta X5 < 0.10$  kPa/L/s).

<sup>a</sup> =  $p < 0.05$  (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>High</sup>

<sup>b</sup> =  $p < 0.05$  (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>Intermediate</sup>

**Supplementary table 2.** Summary of patients that were lost to follow-up between baseline and 6 month visits (n=15)

| <b>Reason for loss of follow up</b>                           | <b>Number of patients,<br/>n (%)</b> |
|---|--------------------------------------|
| Not contactable   | 10 (66.6)                            |
| Unable to produce technically acceptable oscillometry results | 1 (6.7)                              |
| Withdrawn due to a change in medical circumstances            | 4 (26.7)                             |



**Supplementary table 3.** 6 month characteristics in different EFL groups, n=54<sup>a</sup>

| Characteristic                       | EFL <sup>None</sup> (n=24) | EFL <sup>Intermediate</sup> (n=11) | EFL <sup>High</sup> (n=19)           | ANOVA p-value |
|--------------------------------------|----------------------------|------------------------------------|--------------------------------------|---------------|
| Post-BD FEV1 (% predicted)           | 74.8 (68.9-80.7)           | 64.7 (51.9-77.5)                   | <sup>b b</sup> 54.4 (46.3-62.5)      | <0.01         |
| Post-BD FEV1 (L)                     | 2.0 (1.8-2.2)              | 1.7 (1.3-2.1)                      | <sup>b b</sup> 1.4 (1.1-1.6)         | <0.01         |
| Post-BD FVC (% predicted)            | 102.7 (92.3-114.1)         | 99.8 (87.0-112.5)                  | 95.0 (84.0-106.1)                    | 0.60          |
| Post-BD FVC (L)                      | 3.4 (2.9-3.9)              | 3.3 (2.7-3.9)                      | 3.1 (2.7-3.6)                        | 0.66          |
| FEV <sub>1</sub> reversibility (%)   | 10.0 (6.6-13.3)            | 11.9 (5.3-18.4)                    | 17.6 (9.2-26.0)                      | 0.14          |
| FEV <sub>1</sub> reversibility (mls) | 165.8 (112.4-219.3)        | 159.1 (90.8-227.4)                 | 194.2 (110.0-278.4)                  | 0.75          |
| FEV <sub>1</sub> /FVC ratio (%)      | 54.5 (48.3-60.6)           | 52.4 (45.5-59.3)                   | <sup>b</sup> 43.8 (37.5-50.2)        | 0.04          |
| R5 (kPa/L/s)                         | 0.44 (0.39-0.49)           | 0.56 (0.47-0.65)                   | <sup>b b, d</sup> 0.72 (0.63-0.81)   | <0.01         |
| R20 (kPa/L/s)                        | 0.36 (0.32-0.40)           | 0.37 (0.31-0.44)                   | 0.38 (0.33-0.42)                     | 0.77          |
| R5-R20 (kPa/L/s)                     | 0.09 (0.06-0.11)           | <sup>c</sup> 0.19 (0.15-0.22)      | <sup>b b, d d</sup> 0.35 (0.28-0.41) | <0.01         |
| AX                                   | 1.03 [0.10-2.64]           | <sup>c</sup> 2.12 [0.62-4.22]      | <sup>b b, d</sup> 4.48 [1.76-11.69]  | <0.01         |
| X5 (kPa/L/s)                         | -0.17 [-0.27-(-0.07)]      | -0.24 [-0.41-(-0.11)]              | <sup>b b</sup> -0.39 (-1.00(-0.07))  | <0.01         |
| ΔX5 (kPa/L/s)                        | 0.01 [-0.07-0.09]          | <sup>c c</sup> 0.18 [0.11-0.25]    | <sup>b b</sup> 0.57 [0.29-1.55]      | <0.01         |
| TLC (L)                              | 6.16 (5.56-6.76)           | 5.99 (5.08-6.90)                   | 6.25 (5.58-6.91)                     | 0.89          |
| TLC (% predicted)                    | 103.00 (77.32-136.8)       | 98.26 (65.05-130.08)               | 99.85 (74.63-149.00)                 | 0.64          |
| FRC (L)                              | 3.43 [2.06-7.79]           | 3.78 [2.24-5.23]                   | 4.25 [1.96-6.41]                     | 0.11          |
| FRC (% predicted)                    | 109.30 [74.00-196.80]      | 124.80 [69.14-160.60]              | 133.60 [69.00-266.00]                | 0.08          |
| RV(L)                                | 2.61 [1.62-5.81]           | 3.08 [1.92-4.34]                   | 3.61 [1.49-5.59]                     | 0.08          |
| RV (% predicted)                     | 121.10 [68.00-213.00]      | 127.50 [92.00-106.80]              | 146.60 [68.00-265.00]                | 0.10          |
| RV:TLC                               | 0.45 [0.31-0.61]           | 0.49 [0.35-0.73]                   | <sup>b</sup> 0.55 [0.34-0.69]        | 0.03          |
| DLCO (mmol/min/kPa)                  | 4.50 [1.80-9.80]           | 3.90 [2.80-7.0]                    | 4.0 [2.0-6.90]                       | 0.67          |
| DLCO (% predicted)                   | 55.0 [25.0-92.0]           | 42.0 [34.0-90.0]                   | 48.0 [31.0-86.3]                     | 0.48          |
| KCO (mmol/min/kPa/L)                 | 0.96 [0.00-1.50]           | 0.95 [0.53-1.54]                   | 0.85 [0.47-1.44]                     | 0.86          |
| KCO (% predicted)                    | 64.86 [54.31-75.41]        | 71.39 [55.10-87.68]                | 68.72 [58.00-79.45]                  | 0.73          |
| VA (L)                               | 4.61 [3.95-5.27]           | 4.51 [3.62-5.40]                   | 4.41 [3.94-4.87]                     | 0.88          |

|                         |                  |                   |                  |      |
|-------------------------|------------------|-------------------|------------------|------|
| <b>VA (% predicted)</b> | 81.0 [0.0-103.0] | 76.0 [58.0-106.0] | 76.0 [54.0-96.0] | 0.40 |
|-------------------------|------------------|-------------------|------------------|------|

---

Data presented as mean (95% CI), median [range] or percentage as appropriate. p-value corresponds to one way ANOVA, Kruskal-wallis or chi-squared test as appropriate. EFL defined as EFL<sup>High</sup> ( $\Delta X5 \geq 0.28$  kPa/L/s), EFL<sup>Intermediate</sup> ( $\Delta X5$  0.10-0.27 kPa/L/s) and EFL<sup>None</sup> ( $\Delta X5 < 0.10$  kPa/L/s).

<sup>a</sup> 1 patient did not produce technically acceptable results for lung volumes or spirometry

<sup>b</sup> = p<0.05, <sup>b b</sup> = p<0.01 (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>High</sup>

<sup>c</sup> = p<0.05, <sup>c c</sup> = p<0.01 (using Tukey's or Dunns post-hoc test) for EFL<sup>None</sup> vs EFL<sup>Intermediate</sup>

<sup>d</sup> = p<0.05, <sup>d d</sup> = p<0.01 (using Tukey's or Dunns post-hoc test) for EFL<sup>Intermediate</sup> vs EFL<sup>High</sup>

Abbreviations: AX, reactance area; BD, bronchodilator; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; KCO, carbon monoxide transfer coefficient; RV, residual volume; R5, resistance at 5Hz; R20, resistance at 20Hz; TLC, total lung capacity; VA, alveolar volume; X5, reactance at 5Hz,  $\Delta X5$ , difference in total reactance between inspiration and expiration;